Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Anticholinergic

or Botanical

or Dissociative

Use the filters below to narrow your results.

None (41) · Akineton (1) · Artane (1) · Cogentin (1) · DXM (1) · DXO (1) · Spravato (1) · Transderm (1)

Muscarinic receptor antagonist (4) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

None (47) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (47) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (47) · 28 mg/device (each dose uses 2 devices) (1)

None (47) · 84 mg per session (1)

None (47) · Intranasal (under direct medical supervision) (1)

None (47) · Within hours of first administration (1)

None (47) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (47) · ~7-12 hours (1)

None (47) · ~48% intranasal (1)

None (47) · Avoid; may cause fetal harm (1)

None (47) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 49 results in range #1 to #49.

2

2-FDCK

3

4

4-MeO-PCP

7

7-Hydroxymitragynine

A

B

C

Calea zacatechichi

D

E

H

I

P

S

T

X

Xenon

Y

Yopo

2

3

4

7

A

B

C

D

E

H

I

K

M

N

O

P

S

T

X

Y